Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Background: Erythropoiesis-stimulating agents are used to treat anemia in patients with
cancer. However, their safety and effectiveness is controversial. We did a systematic review …
cancer. However, their safety and effectiveness is controversial. We did a systematic review …
[HTML][HTML] Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
J Glaspy, J Crawford, J Vansteenkiste, D Henry… - British journal of …, 2010 - nature.com
BACKGROUND: Cancer patients often develop the potentially debilitating condition of
anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents …
anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents …
[HTML][HTML] Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes
D Cella, D Dobrez, J Glaspy - Annals of Oncology, 2003 - Elsevier
Background Anemia occurs frequently in patients with cancer and is associated with
impaired health-related quality of life (HRQOL). Treatment of anemia results in significant …
impaired health-related quality of life (HRQOL). Treatment of anemia results in significant …
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
J Bohlius, K Schmidlin, C Brillant, G Schwarzer… - The Lancet, 2009 - thelancet.com
Background Erythropoiesis-stimulating agents reduce anaemia in patients with cancer and
could improve their quality of life, but these drugs might increase mortality. We therefore did …
could improve their quality of life, but these drugs might increase mortality. We therefore did …
Management of anemia in cancer patients
A Calabrich, A Katz - Future oncology, 2011 - Future Medicine
Cancer-related anemia adversely affects quality of life and is associated with reduced
overall survival. The correction of anemia in cancer patients has the potential to improve …
overall survival. The correction of anemia in cancer patients has the potential to improve …
Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns
R Stasi, S Amadori, TJ Littlewood, E Terzoli… - The …, 2005 - academic.oup.com
The management of cancer-related anemia with erythropoietic agents presents many
unresolved issues. We reviewed the literature relating to epoetin alfa (Eprex®/Epypo®; …
unresolved issues. We reviewed the literature relating to epoetin alfa (Eprex®/Epypo®; …
The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents
R Mhaskar, H Wao, B Miladinovic… - Cochrane Database …, 2016 - cochranelibrary.com
Background Erythropoiesis‐stimulating agents (ESAs) are commonly used to treat
chemotherapy‐induced anemia (CIA). However, about half of patients do not benefit …
chemotherapy‐induced anemia (CIA). However, about half of patients do not benefit …
Erythropoietin or darbepoetin for patients with cancer
T Tonia, A Mettler, N Robert… - Cochrane Database …, 2012 - cochranelibrary.com
Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
Erythropoietin for patients with malignant disease
JJB Bohlius, S Langensiepen… - Cochrane Database …, 2004 - cochranelibrary.com
Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
Erythropoietin or Darbepoetin for patients with cancer‐meta‐analysis based on individual patient data
J Bohlius, K Schmidlin, C Brillant… - Cochrane database …, 2009 - cochranelibrary.com
Background Erythropoiesis‐stimulating agents (ESAs) reduce anemia in cancer patients
and may improve quality of life, but there are concerns that ESAs might increase mortality …
and may improve quality of life, but there are concerns that ESAs might increase mortality …
Related searches
- patients with cancer meta analysis
- agents for anemia meta analysis
- safety outcomes meta analysis
- cancer meta erythropoietin or darbepoetin
- patients with cancer agents and mortality
- clinical outcomes erythropoietic agents
- management of anemia cancer patients
- agents and mortality meta analysis
- agents in oncology meta analysis
- cancer meta darbepoetin for patients
- mortality in patients meta analysis
- darbepoetin for patients meta analysis
- erythropoietin or darbepoetin meta analysis
